KBP 7072

Drug Profile

KBP 7072

Alternative Names: KBP7072

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator KBP Biosciences
  • Class Hexoses; Ketoses; Small molecules; Sulfonic acids
  • Mechanism of Action Immunomodulators; Mitochondrial permeability transition pore modulators; Sodium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bacterial infections

Most Recent Events

  • 26 Oct 2016 Positive safety and pharmacokinetic data from a phase I trial in Bacterial infections (In volunteers) released by KBP Biosciences
  • 30 Dec 2015 KBP Biosciences completes a phase I trial for Bacterial infections (In volunteers) in USA (NCT02654626)
  • 01 Oct 2015 KBP Biosciences initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT02654626)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top